This is less a litigation story than a credibility reset for the entire “locally acting / gut-restricted” biotech subtheme. Once a platform claim becomes the issue, the market stops underwriting the mechanism and starts underwriting the regulator’s interpretation of exposure and off-target risk; that usually means a higher probability of program delay, higher trial cost, and a lower exit multiple even if the molecule survives. The immediate loser is AARD, but the second-order loser is any early-stage oral peptide or GI-targeted developer with a similar safety narrative, because diligence comps get repriced before the next datapoint.

The next 1-3 months are about FDA process, not science. A clinical hold tends to compress valuation toward cash-on-hand minus burn-adjusted optionality, and the real risk is that management now needs new safety work or formulation changes before re-entry, which can push the cash runway into financing territory. If the hold persists through the next quarter, the market will likely start treating the asset as a salvage case rather than a Phase 3 readout story.

Contrarian view: the selloff may already discount a lot of terminal bad news, so the trade is no longer about headline risk but about whether there is hidden balance-sheet value or a fast path to hold lift. What would falsify the bearish setup is a clean FDA resolution, public data showing exposure is still meaningfully localized at clinically relevant doses, or a credible partnering event that validates the asset despite the hold. Absent that, rallies are likely to be sellable because litigation overhang plus regulatory uncertainty usually cap multiple recovery for many quarters.